Life Science Nation Newsletter  |  August 20, 2015  |  Issue 125

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Aug. 13 - Aug. 19)
Seeking Medical Device, Diagnostics and HIT Investment Opportunities
Looking for Partnering and In-Licensing Opportunities Globally
Seeking Innovative Technologies in Oncology, Immunology, and Hematology
Looking to Invest in Healthcare IT and Connected Devices
In This Issue
Innovation In Spotlight at RESI

       READ MORE
Chapter 13: "Straight Talk About Finding, Vetting, and Closing Capital"
Venture Philanthropy Panel Announcement: RESI Boston

LSN Videos
Video Recap of [email protected] 2015

[email protected] Investor Panel Videos

LSN in the News
Innovation In Spotlight at RESI
By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Life Science Nation unveiled the finalists that were hand-picked to enter the RESI Boston Innovation Challenge: an exciting group of innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare information technology (HC IT).

As RESI returns to the Boston-Cambridge life science hub, the Innovation Challenge has received unprecedented amount of interest. The RESI scientific team has gone through rigorous review and independently hand-picked top companies, who will showcase their innovations in the RESI exhibition hall...


Chapter 13: "Straight Talk About Finding, Vetting, and Closing Capital"
By Lucy Parkinson, Senior Research Manager, LSN    

Following the overview of the fundraising process in Chapter 12, we get into some of the nitty-gritty areas and explore a few common pitfalls and how to avoid them. Chapter 13 discusses the importance of getting on the road or hitting the phone to engage with relevant investors, and why it's important to ensure that all the investor prospects you speak with are kept in context regarding the deal. Finally, the chapter explores how to prioritize your prospects to use your runway time most effectively while raising money.

Venture Philanthropy Panel Announcement: RESI Boston
By Michael Quigley, Director of Research, LSN

Venture philanthropy has become an increasingly significant source of capital for the earliest stages of company development in the life science space. Often looking to help bridge the gap between angel and venture capital financing, these groups have improved patient outcomes as their bottom line and look to use their financial returns from investments to improve that metric further. Financing is far from the only thing venture philanthropy groups can bring to an early stage company; they can often supply access to patients and experts in their field, access to tissue banks, and connections to donors.

At RESI in Boston this Sept. 16th we will be bringing together 5 experts in the venture philanthropy space to discuss the various ways that they can work with and help early stage life science companies.

In a panel moderated by Chris de Souza, Director of Broadview Ventures, the audience will hear from:
  • David Sandak, VP of Strategy and Research, Accelerate Brain Cancer Cure
  • Daniel Smith, President, Autism Speaks
  • Jit Patel, VP of Research and Business Development, JDRF [Juvenile Diabetes Research Foundation]
  • Usha Arunachalam, VP Business Development for Research, Leukemia & Lymphoma Society
If venture philanthropy investment is part of the plan to get your company funded or to its next inflection point, this panel presents a great opportunity to broaden your network while expanding your understanding of these organizations.